← Back to Drug List

EMTRICITABINE/ TENOFOVIR TAB

Clinical Criteria Summary

Indications & Target Populations

  • HIV preexposure prophylaxis (PrEP) for men who have sex with men (MSM), transgender women (TGW), cisgender men, and cisgender women at risk for HIV sexual acquisition.
  • Patients at very high risk of transmission (e.g., frequent condom-less sexual encounters, partners with uncontrolled HIV infection).

Renal & Skeletal Considerations

  • Alternative to oral PrEP for patients with renal dysfunction.
  • Unlikely to impact renal function or bone mineral density.
  • Appropriate alternative for patients with osteoporosis or osteopenia.

Adherence & Behavioral Factors

  • Beneficial for patients unable to adhere to daily oral dosing due to unstable housing, stigma, cognitive difficulties, uncontrolled mental illness, or substance use disorders.
  • Requires patient agreement to comply with a strict every-2-month injection and testing schedule.
  • Long half-life may pose a risk if therapy is abruptly discontinued while continuing high-risk behaviors (subtherapeutic concentrations may persist for up to 1 year, increasing resistance risk).

Contraindications & Drug Interactions

  • Should not be used in patients receiving strong CYP inducers.
  • Indicated for patients with contraindications or intolerance to tenofovir or emtricitabine.

Monitoring & Testing Requirements

  • HIV must be excluded at baseline and at least every 2 months while on therapy.
  • Adherence counseling and support required; patients educated on side effects, particularly during the first month of therapy.
  • Additional monitoring (e.g., sexually transmitted infections, serum lipids, weight) per CDC/USPSTF guidelines.

Administration & Prescribing Requirements

  • Long-acting intramuscular injection formulation.
  • Oral lead-in is optional but may be used to assess early tolerance prior to long-lasting injection; oral CAB must be procured from Theracom.
  • Prior authorization (PA-F) on the VA National Formulary (VANF).
  • Must be prescribed by Infectious Diseases, HIV, or other PrEP providers with training/experience in managing HIV PrEP patients.

Source Documents